Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of “Moderate Buy” by Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned a consensus rating of “Moderate Buy” from the twenty-nine analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $817.8750.

REGN has been the topic of a number of analyst reports. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 14th. Finally, Sanford C. Bernstein upped their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $579.34 on Wednesday. The stock has a market capitalization of $61.40 billion, a P/E ratio of 14.60, a PEG ratio of 1.80 and a beta of 0.31. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $575.71 and its 200 day moving average is $562.26. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $972.74.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company posted $11.56 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.87%.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 31 shares in the last quarter. Activest Wealth Management raised its position in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Finally, Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $27,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.